PPARG and COVID-19: A study employing a public database on subjects with type 2 diabetes and COVID-19, along with animal studies, revealed that the PPARγ agonist pioglitazone may ameliorate acute lung injury and SARS-CoV-2-mediated hyperinflammation [83].